- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Not So Different: How Pharmacists Can Help Boost Biosimilar Uptake
Sonia T. Oskouei, PharmD, BCMAS, DPLA, from Cardinal Health, highlights ways pharmacists can be proactive in the effort to improve biosimilar uptake in the United States.
As the US biosimilar industry continues to expand, physicians, payers, and pharmaceutical companies have been at the forefront of the discussion on how to increase biosimilar uptake and education efforts. However, pharmacists also have a role to play in sharing information and encouraging uptake.
The lack of interchangeability designations for US biosimilars prevents pharmacists from being able to switch out costly originator drugs with more affordable biosimilars. They must get approval from a physician first. There are other ways, though, that pharmacists can help uptake efforts.
We sat down with Sonia T. Oskouei, PharmD, BCMAS, DPLA, vice president of Biosimilars at Cardinal Health to discuss the power that pharmacists have in facilitating biosimilar uptake in the United States and what health care organizations can do to empower pharmacists further.
To learn more about Sonia’s work, click here.
To learn more about pharmacists’ role in promoting biosimilars, click here.
Biosimilars Policy Roundup for March 2023—Podcast Edition
April 2nd 2023On this episode of Not So Different, we discuss some of the global biosimilar policy news that came out during the month of March, including a new bill in Congress and 2 Canadian jurisdictions implementing switching policies.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
AAM's Craig Burton: Is the Biden Administration Doing Enough to Help Biosimilars?
November 13th 2022Craig Burton, senior vice president of policy and strategic alliances at the Association for Accessible Medicines and executive director of the Biosimilars Council, gives insight into the many health policies that the Biden administration has implemented in 2022 as well as their possible impact on biosimilar adoption.
